U.S. Food and Drug Administration PDUFA dates on the calendar for July include an NDA review for Jazz Pharmaceuticals’ experimental medicine for cataplexy.
https://www.pharmalive.com/wp-content/uploads/2020/07/FDA-Action-Alert-Jazz-ANI-and-Ultragenyx-BioSpace-7-20-10.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-07-20 12:01:302020-07-24 17:36:04FDA Action Alert: Jazz, ANI and Ultragenyx